Koers Reshape Lifesciences Inc Nasdaq
Aandelen
US7611234052
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 9,99 mln. 9,36 mln. | Omzet 2025 * | 11,99 mln. 11,23 mln. | Marktkapitalisatie | 3,8 mln. 3,56 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -6 mln. -5,62 mln. | Nettowinst (verlies) 2025 * | -5 mln. -4,68 mln. | EV/omzet 2024 * | 0,38 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,32 x |
K/w-verhouding 2024 * |
-0,36
x | K/w-verhouding 2025 * |
-0,45
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,83% |
Recentste transcriptie over Reshape Lifesciences Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 01-02-20 |
Director of Finance/CFO | 63 | 15-06-21 | |
Dov Gal
CMP | Compliance Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 01-01-16 |
Dan Gladney
CHM | Chairman | 70 | 01-11-15 |
Director/Board Member | 70 | 15-06-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,78% | 220 mld. | |
+6,18% | 183 mld. | |
+10,62% | 133 mld. | |
+24,53% | 107 mld. | |
-0,95% | 63,05 mld. | |
+11,29% | 51,74 mld. | |
+4,81% | 50,47 mld. | |
-0,94% | 40,91 mld. | |
+24,28% | 31,91 mld. |